Experimental study on the treatment of rheumatoid arthritis associated interstitial pulmonary disease with JAK inhibitor tofacitinib
10.19405/j.cnki.issn1000-1492.2023.05.019
- Author:
Zong Jiang
1
;
Xiaoling Yao
1
;
Fang Tang
2
;
Wukai Ma
2
;
Weiya Lan
2
;
Xueming Yao
2
;
Yang An
2
;
Zhengqi Liu
2
Author Information
1. Second School of Clinical Medicine , Guizhou University of Traditional Chinese Medicine , Guiyang 550002
2. Dept ofRheumatology and immunology, the Second Afiliated Hospital of Guizhou University of Traditional Chinese Medicine , Guiyang 550003
- Publication Type:Journal Article
- Keywords:
JAK⁃STAT;
tofacitinib;
rheumatoid arthritis;
interstitial lung disease
- From:
Acta Universitatis Medicinalis Anhui
2023;58(5):819-823
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the effects of the tofacitinib on interstitial lung disease( ILD) by regulating the JAK⁃STAT signaling pathway.
Methods:Wistar rats were randomly divided into 4 groups:normal group , ILD group ,prednisone acetate group , and tofacitinib group. Except for the normal group , the other three groups were given 3mg/ml bleomycin solution for modeling. After 28 days of intragastric administration , the lung tissues of all rats were
collected for hematoxylin⁃eosin staining ( HE) and Western blot ( WB) to detect the protein levels of JAK1 and STAT1;Enzyme⁃linked immunosorbent assay(ELISA) was used to detect tumor necrosis factor in rat serum (TNF) Ⅳ α , interleukin (IL) Ⅳ6 , IL⁃10 , IL⁃1β .
Results :HE staining of lung tissue in ILD ,prednisone acetate group and tofacitinib group showed alveolar tissue thickening , alveolar wall capillary congestion , bronchial luminal epithelial cells shedding, and inflammatory cell exudation. The results of WB showed that JAK1 and STAT1 significantly increased in ILD group , and decreased in different degrees compared with ILD group , tofacitinib group and prednisone acetate group (P < 0. 05) . The ELISA results showed that the expressions of serum TNF⁃α , IL⁃6 and IL⁃1β in the ILD group were significantly higher than those in the normal group (P < 0. 01) . The expression of pine group decreased (P < 0. 05) , and the expression of IL⁃10 was the opposite.
Conclusion:Tofacitinib reduces lung tissue damage and the inflammatory response in the treatment of ILD by inhibiting the JAK⁃STAT pathway and down⁃regulating the expression of inflammatory factors TNF⁃α , IL⁃6 , IL⁃1β and up⁃regulating the anti⁃inflammatory factor IL⁃10.
- Full text:2024081222022483923JAK抑制剂托法替布治疗类...炎相关间质性肺病的实验研究_蒋总.pdf
